ABPI has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.
The Association of the British Pharmaceutical Industry (ABPI) has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.
According to a Sept. 7, 2021 press release, the industry body started searching for new council members in June 2021. The aim of the council is to steer and broaden the association’s strategic thinking by bringing together industry and patient advocates. New members of the council are Charlotte Augst from National Voices, Emily Crossley from Duchenne UK, Jane Lyons from Cancer52, Tom Nutt from Meningitis Now, Hilary Reynolds from the Association of Medical Research Charities, Jayne Spink from Prostate Cancer Research, Bob Stevens from the MPS Society, and Neil Tester from the Richmond Group.
“We have had an overwhelming response to our search for a new Patient Advisory Council, and we are really proud to name these eight passionate experts as our inaugural members,” said Colette Goldrick, executive director of Strategy, Research & Partnerships at the ABPI, in the press release. “Each is a leader in their community, and we are really looking forward to hearing what they have to say and how we can work together towards meaningful change.”
“The council was formed with the sole purpose of ensuring the association, our board, and the industry at large has a greater understanding of the patient experience, and how our work can help improve the lives of patients and their families,” added Ben Osborn, president of the ABPI. “We’re excited to get started.”
Source: ABPI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.